AC Immune (ACIU) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report issued on Monday, February 4th, The Fly reports. HC Wainwright currently has a $8.00 price target on the stock. The analysts noted that the move was a valuation call.

A number of other research analysts have also recently weighed in on ACIU. Zacks Investment Research cut shares of AC Immune from a buy rating to a hold rating in a research note on Tuesday, October 9th. BidaskClub raised shares of AC Immune from a strong sell rating to a sell rating in a research note on Friday, October 12th. Leerink Swann assumed coverage on shares of AC Immune in a research note on Monday, November 12th. They issued an outperform rating and a $18.00 target price for the company. Finally, UBS Group assumed coverage on shares of AC Immune in a research note on Friday, January 4th. They issued a buy rating and a $16.00 target price for the company. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $12.10.

Shares of ACIU traded down $0.06 during mid-day trading on Monday, reaching $4.56. 538,044 shares of the company’s stock were exchanged, compared to its average volume of 1,256,970. AC Immune has a 52-week low of $3.25 and a 52-week high of $17.40. The stock has a market cap of $300.32 million, a price-to-earnings ratio of -15.20 and a beta of -0.09.

Several large investors have recently bought and sold shares of the stock. Barclays PLC lifted its holdings in shares of AC Immune by 726.2% during the 4th quarter. Barclays PLC now owns 6,378 shares of the company’s stock valued at $61,000 after acquiring an additional 5,606 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of AC Immune during the 4th quarter valued at $121,000. Marshall Wace LLP acquired a new position in shares of AC Immune during the 3rd quarter valued at $107,000. GSA Capital Partners LLP acquired a new position in shares of AC Immune during the 3rd quarter valued at $110,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of AC Immune during the 3rd quarter valued at $142,000. Institutional investors and hedge funds own 30.17% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

See Also: What is a recession?

The Fly

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.